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L
ymphangioleiomyomatosis (LAM) is a rare
lung disease, which occurs sporadically or
in association with the genetic disease
tuberous sclerosis complex (TSC) [1, 2]. Sporadic
LAM affects ,1 in 400,000 adult females; in TSC,
LAM occurs in 30–40% of adult females [3, 4] and
exceptionally in males and children [5, 6].
Patients with LAM usually develop progressive
dyspnoea and recurrent pneumothorax, chylous
collections and occasional haemoptysis [1]. Extra
pulmonary lymphadenopathy and cystic masses
of the axial lymphatics termed lymphangioleio-
myomas can result in abdominal and pelvic
lymphatic obstruction [7]. LAM is often asso-
ciated with angiomyolipoma in the kidneys [8],
and an increased frequency of meningioma [9].
LAM varies in clinical features and rate of
progression: this together with an absence of
clear prognostic factors results in patients being
given conflicting information about prognosis.
Diagnosis is made by tissue biopsy (generally
from the lung but occasionally from lymph nodes
or lymphangioleiomyomas) and/or a combination
of history and high-resolution computed tomo-
graphy scanning (HRCT). Pathological diagnosis
relies on characteristic LAM cell morphology and
positive immunoreactivity to smooth muscle actin
and HMB-45 antibodies. Increasingly HRCT is
used to diagnose LAM without resorting to lung
biopsy; however a number of conditions with
multiple pulmonary cysts can mimic LAM.
As LAM is rare, there have been no controlled trials
of its management. Supportive treatment includes
management of airflow obstruction and hypoxae-
mia with bronchodilators and oxygen respectively,
specific treatment for surgical or pleural complica-
tions including pneumo- and chylothorax, and
interventional treatment of renal lesions [10, 11]. As
LAM is a disease of females and is thought to be
accelerated by oestrogen, oophorectomy, tamoxi-
fen, progesterone and gonadotropin-releasing hor-
mone (GnRH) analogues have been used without
evidence that they are effective. The recent finding
of abnormalities in the TSC1/2 genes resulting in
constitutive activation of the kinase mammalian
target of rapamycin (mTOR) [12, 13] has led to trials
of mTOR inhibitors including sirolimus in patients
with LAM and angiomyolipoma [14, 15].
METHODS
The purpose of the LAM Task Force was to
produce evidence based, consensus guidelines
for the diagnosis, assessment and treatment of
patients with LAM. The two Chairmen designed
the objectives, obtained European Respiratory
Society sponsorship and recruited appropriate
specialists. The Core panel had overall responsi-
bility for the development of the guidelines. The
Consultant panel advised on specialist aspects.
The Review panel reviewed the documents and
comprised all members of the Core and
Consultant panels plus international experts in
LAM, interstitial lung diseases and representa-
tives of European thoracic societies.
The process of guideline development was as
follows: 1) question formulation; 2) evidence
collection and synthesis (Core and Consultant
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panels); 3) grading of recommendation strength using the 2004
American College of Chest Physicians health and science
policy grading system [16] (Core and Consultant panels); 4)
formal review with scoring of agreement and proposals for
modifications using Likert scale statistics and definitions [17]
(Core, Consultant and Review panels); 6) integration of
proposals (Core panel); 7) further iterations of the review
process with re-assessment of agreement (Core, Consultant
and Review panels); and 8) final revision (Core panel). Final
recommendations are scored by 1) strength of recommenda-
tion: from grade A (strongest) to D (weakest) and I (incon-
clusive); 2) quality of evidence (quality); 3) magnitude of
benefit; and 4) strength of expert consensus. Further details are
contained in appendices 1 and 4. A longer version of the
guidelines incorporating further discussion of the evidence is
also available online (www.ersnet.org/LAMguidelines).
PROPOSED DEFINITIONS AND DIAGNOSTIC WORK-UP
FOR LAM
Diagnostic criteria
No studies have been performed which examine the diagnostic
accuracy of strategies which do not include lung biopsy (the
gold standard for diagnosis in most studies). The diagnostic
criteria below result from approaches used by several large
series, registries [3, 18–21] and expert opinion.
Definite LAM
1) Characteristica or compatiblea lung HRCT, and lung biopsy
fitting the pathological criteria for LAMa; or
2) Characteristica lung HRCT and any of the following:
angiomyolipoma (kidney)b; thoracic or abdominal chylous
effusionc; lymphangioleiomyomad or lymph-node involved by
LAMd; and definite or probable TSCe.
Probable LAM
1) Characteristica HRCT and compatible clinical historyf; or
2) Compatiblea HRCT and any of the following: angiomyoli-
poma (kidney)b; and thoracic or abdominal chylous effusionc.
Possible LAM
Characteristica or compatiblea HRCT.
In reference to above text.
a) As defined below.
b) Diagnosed by characteristic CT features and/or on
pathological examination.
c) Based on visual and/or biochemical characteristics of the
effusion.
d) Based on pathological examination.
e) See appendix 2 (available in the online supplementary
material; www.erj.ersjournals.com)
f) Compatible clinical features include pneumothorax (espe-
cially multiple and/or bilateral) and/or altered lung function
tests as in LAM.
Remarks
1) LAM is considered associated with TSC (TSC-LAM) when
TSC is present. Otherwise LAM is considered sporadic.
2) The diagnosis of LAM defined above is only for females.
LAM is very exceptional in males without TSC and exceptional
in males with TSC where diagnosis requires both characteristic
or compatible HRCT and typical pathological features on lung
biopsy.
3) The diagnosis of LAM requires exclusion of the alternative
causes of cystic lung disease (see online supplementary data
p. 18; www.erj.ersjournals.com). A complete diagnostic work-
up for these alternative causes of cystic lung disease is
necessary in patients with probable and especially possible
LAM.
Agreement on diagnostic criteria; Consensus: very good.
Pathologic criteria for diagnosis
Two lesions characterise LAM: cysts and a multifocal nodular
proliferation of immature smooth muscle and perivascular
epithelioid cells (LAM cells) (fig. 1) [22–24]. Both lesions are
found together in variable percentages and the findings may
be inconspicuous in early disease. The sensitivity and
specificity of the pathological changes seen in LAM have not
been addressed. Where a typical proliferation of immature
smooth muscle cells and epithelioid cells outside the normal
muscular structures occur, associated with cyst formation,
routine haematoxylin and eosin staining in combination with
adequate clinical and radiological information is sufficient to
make the diagnosis in most cases. Immunohistochemistry for
smooth muscle actin, desmin and HMB45 is an important
adjunct to diagnosis. HMB45 is particularly useful in samples
obtained by transbronchial biopsy [25]. In rare cases, HMB45
staining is absent but the characteristic lesions are present and
the diagnosis of LAM can still be made [8, 25]. In such cases
correlation with clinical features and CT scan is essential to
increase the confidence level of diagnosis. In about half of cases
the oestrogen and/or progesterone receptor can be detected by
immunohistochemistry [26, 27]. Further details concerning
diagnostic and molecular pathology are provided in appendix
3 (available in the online supplementary material; www.erj.
ersjournals.com).
Recommendations
1) Pathological samples from patients with suspected LAM (or
any diffuse parenchymal lung disease) should be examined by
a pathologist experienced in LAM.
2) LAM should be considered when there is a variable
predominance of cysts, multifocal, nodular proliferating
immature smooth muscle and perivascular epithelioid cells.
3) Immunohistochemistry for a-smooth muscle actin and
HMB45 should be performed especially where morphologic
features do not allow a secure diagnosis to be made. The
oestrogen and progesterone receptor may be an adjunct to
diagnosis.
Grade: expert opinion/A; Quality: expert opinion; Benefit:
substantial; Consensus: very good.
Radiological criteria for diagnosis
Characteristic features of pulmonary LAM on HRCT
HRCT is the recommended imaging technique for the diagnosis,
assessment and follow-up of diffuse infiltrative lung disease
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including LAM [28]. Lung cysts are the hallmark lesion in LAM
and are present in all patients (fig. 2) [29, 30]. Their appearance,
size and contour vary considerably typically ranging from 2–
5 mm in diameter but occasionally as large as 30 mm [31, 32].
Cysts are usually round, distributed evenly throughout the
lungs with normal lung parenchyma. Cyst wall thickness ranges
from barely perceptible to 2 mm in most series [32, 33] but has
been described as measuring up to 4 mm [31].
Recommendations
1) Patients with suspected LAM should have a pulmonary
HRCT scan using a thin collimation, high spatial reconstruc-
tion algorithm.
2) The acquisition may be performed with sequential scanning
(images with 1 mm collimation at 1-cm intervals) or low dose
spiral multidetector CT.
Grade: expert opinion/A; Quality: expert opinion; Benefit:
substantial; Consensus: very good.
Remarks
1) HRCT features characteristic of LAM are multiple (.10)
thin-walled round well-defined air-filled cysts with preserved
or increased lung volume with no other significant pulmonary
involvement specifically no interstitial lung disease with the
exception of possible features of multifocal micronodular
pneumocyte hyperplasia in patients with TSC.
2) HRCT features are compatible with pulmonary LAM when
only few (.2 and f10) cysts as described are present.
Radiology in abdominal LAM
Abdominal CT scanning can be used to detect angiomyolipo-
mas, lymphangioleiomyomas or lymphadenopathy to support
the diagnosis, to plan the management of angiomyolipomas,
and to follow their evolution. Abnormal abdominopelvic
imaging findings in patients with LAM are found in up to
two thirds of patients [7]. CT is more sensitive and specific
than ultrasound and can detect tumours ,1 cm in diameter
[7]. Magnetic resonance imaging (MRI) with and without fat
suppression techniques may be adequate for the diagnosis of
fat-containing tumours when iodinated contrast is contra-
indicated [34].
Recommendations
1) All patients with LAM or suspected LAM should have an
abdomino-pelvic CT at diagnosis or during work-up to
identify angiomyolipoma and other abdominal lesions.
2) The abdomen should be scanned contiguously with f3 mm
collimation, before and after the intravenous administration of
non-ionic contrast.
3) Since a proven therapeutic intervention is not currently
available for lymphangioleiomyomas, screening of asympto-
matic patients for lymphangioleiomyomas during the course of
the disease should not be performed.
4) Patients with abdominal symptoms should be evaluated for
the presence of lymphadenopathy or lymphangioleiomyomas
by CT scanning.
Grade: C; Quality: low; Benefit: intermediate; Consensus: very
good.
Screening for meningioma in patients with sporadic LAM
Patients with LAM have an increased risk of meningioma [9],
the growth of which may be promoted by progesterone. These
lesions should be identified especially in patients receiving
progesterone. Brain imaging is also useful in the work-up of
possible TSC in patients with LAM.
Recommendations
1) Brain MRI as a baseline evaluation may be useful for
comparison during follow-up and should be performed in the
presence of symptoms compatible with meningioma. Grade: C;
Quality: low; Benefit: intermediate; Consensus: very good.
2) Brain MRI screening for meningioma should be performed
in females with LAM receiving progestative drugs or planned
to receive such treatment. Grade: expert opinion/B; Quality:
expert opinion; Benefit: intermediate; Consensus: very good.
FIGURE 1. Lung biopsies showing proliferating nodules of lymphangioleio-
myomatosis cells at low and high power stained with haematoxylin and eosin.
Further pathological images are shown in supplementary figure 3 (www.erj.
ersjournals.com).
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Work-up for TSC in patients with LAM
Patients presenting with apparent sporadic LAM may have
TSC. As TSC has a highly variable phenotype and two thirds of
cases arise as spontaneous mutations the diagnosis can be
overlooked. Patients should undergo a full history and
physical examination to exclude TSC. Where doubt exists,
referral to a clinical geneticist should be made. Diagnostic
criteria for TSC and recommendations for assessment of
patients are provided in appendix 2 (available in the online
supplementary material; www.erj.ersjournals.com) [35].
Recommendations
1) Patients presenting with LAM should have a thorough
personal and family history taken concerning the manifesta-
tions of TSC. Physical examination should include the skin,
retina and nervous systems by a physician familiar with the
manifestations of TSC. Grade: B; Quality: low; Benefit:
substantial; Consensus: very good.
2) Patients with LAM and bilateral angiomyolipoma, and other
patients where doubt remains, should be referred to a clinical
geneticist for full evaluation. Grade: D; Quality: low; Benefit:
substantial; Consensus: very good.
3) Routine genetic analysis of patients with sporadic LAM is
not of benefit and should not be performed. Grade: D; Quality:
low; Benefit: negative; Consensus: very good.
Lung function testing
Forced expiratory volume in 1 s (FEV1) and transfer factor of
the lung for carbon monoxide (TL,CO) correlate with CT and
histological abnormalities in LAM and change over time as the
disease progresses [4, 30, 36]. TL,CO, abnormal in more patients
than FEV1, may be a more sensitive indicator of early disease.
Cardiopulmonary exercise testing may provide additional
information especially in patients with milder disease but is
more difficult to obtain and perform in a reproducible manner.
The rate of decline in FEV1 and TL,CO varies between
individuals and it remains difficult to predict the clinical
course in individuals and hence how often to repeat lung
function. Most physicians initially perform standard lung
function tests every 3–6 months. In patients with stable
disease, after a period of observation this may be increased
to yearly intervals.
Recommendations
1) Spirometry, bronchodilator testing and TL,CO should be
performed in the initial evaluation of patients with LAM
(including TSC-LAM). Grade: B; Quality: low; Benefit: sub-
stantial; Consensus: very good.
2) FEV1 and TL,CO should be performed to assess disease
progression and response to treatment. Grade: B; Quality: low;
Benefit: substantial; Consensus: very good.
3) Lung function tests should be repeated every 3–6 months in
patients with progressive disease and every 6–12 months in
those with more stable disease, as determined by a period of
observation of 1 yr. Grade: C; Quality: low; Benefit: inter-
mediate; Consensus: very good.
Arterial blood gas measurement
Arterial hypoxaemia is common in LAM [18, 20, 37]. Blood
gases do not provide useful information above that obtained
by pulse oximetry in the assessment of patients with mild to
moderate disease. However, they provide baseline data and in
advanced disease may be useful to define the indication for
oxygen therapy, especially for transplant evaluation and to
exclude hypercapnia [38].
Recommendations
1) Blood gases may be performed at initial evaluation of
patients with LAM to obtain a baseline value, and in the
assessment of patients with severe disease including before
transplant referral. Grade: expert opinion/A; Quality: expert
opinion; Benefit: substantial; Consensus: very good.
2) Blood gases should be performed to assess the indication for
oxygen therapy in patients with advanced disease. Grade:
expert opinion/A; Quality: expert opinion; Benefit: substantial;
Consensus: very good.
FIGURE 2. (a) High-resolution computed tomography (CT) scan showing
typical changes in a patient with moderate lymphangioleiomyomatosis, compli-
cated of a right pneumothorax. (b) CT of an asymptomatic renal angiomyolipoma
showing characteristic heterogeneous lesion in the left kidney (arrow). Further lung,
renal and abdominal CT images are shown in supplementary figure 2 (www.erj.
ersjournals.com).
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Cardiopulmonary exercise testing and 6-min walk test
Exercise performance and maximal oxygen uptake (V9O2,max)
are impaired in patients with LAM [39]. The 6-min walk test
(6MWT) is likely to be helpful in evaluating exercise
performance in patients with LAM [40].
Recommendations
1) Cardiopulmonary exercise testing may be performed to
provide additional information over standard lung function
tests in symptomatic patients. Grade: C; Quality: low; Benefit:
small/weak; Consensus: very good.
2) The 6MWT may be performed in the evaluation of disability,
disease progression and response to treatment in symptomatic
patients Grade: expert opinion/B; Quality: expert opinion;
Benefit: intermediate; Consensus: very good.
Screening for pulmonary hypertension
Pulmonary hypertension has not been reported frequently in
cohorts of patients with LAM [39]. No data are available on the
efficacy of treatment of pulmonary hypertension in LAM.
Recommendations
1) Screening for pulmonary hypertension is not recommended
in patients with non-severe LAM. Grade: inconclusive;
Quality: low; Benefit: conflicting; Consensus: very good.
2) Estimation of pulmonary artery pressure by echocardio-
graphy may be performed in patients with severe disease and
those requiring long-term oxygen therapy. Pulmonary artery
pressure should be estimated in those considered for lung
transplantation. Grade: C; Quality: low; Benefit: intermediate;
Consensus: very good.
SCREENING FOR LAM IN AT RISK GROUPS
Delays between first symptom and diagnosis suggest that in
many patients LAM is either not detected for many years or
patients are wrongly diagnosed with another disease. Patients
may benefit from several low-risk interventions including
education on the symptoms of pneumothorax, avoidance of
oestrogen containing treatments, prophylactic vaccination
against influenza and pneumococcus, smoking cessation
measures and monitoring to detect progression at an earlier
stage, possibly allowing patients to participate in clinical
studies.
Is CT indicated in females with apparently spontaneous
pneumothorax?
The low prevalence of LAM does not justify chest CT for
diagnosing LAM for the first pneumothorax. It may be justified
for the second pneumothorax, and should be carried out for
the third (and more) pneumothorax, especially in nonsmoking
females, and if symptoms (e.g. dyspnoea) are present before
the pneumothorax.
Recommendations
1) Chest CT for patients with a first-time pneumothorax should
not be performed routinely. Grade: I; Quality: low; Benefit:
conflicting; Consensus: good.
2) Chest CT may be indicated to evaluate the presence of LAM
that is suspected clinically but is not apparent on standard
radiographs. Grade: C; Quality: low; Benefit: small/weak;
Consensus: good.
3) The panel did not achieve consensus regarding the utility of
chest CT scans for evaluating patients with recurrent pneu-
mothoraces, persistent air leaks, or planned surgical interven-
tions. Grade: I; Quality: low; Benefit: conflicting; Consensus:
none.
Should females with TSC undergo screening for LAM by
HRCT scan?
In total, 26–39% of females with TSC have lung cysts consistent
with LAM [2, 41, 42]. Most have no symptoms of lung disease
and the natural history of LAM detected by screening in TSC is
not known [43]. However detection of LAM in otherwise
asymptomatic patients may allow the interventions mentioned
previously. As clinical examination, chest radiography and
lung function tests may all be normal in the presence of LAM.
HRCT is the investigation of choice to detect LAM in these
patients.
Recommendations
1) Females with TSC should undergo screening for LAM by
HRCT of the thorax at the age of 18 yrs and if negative again at
the age of 30–40 yrs. Grade: C; Quality: low; Benefit:
intermediate; Consensus: very good.
2) HRCT should be repeated if persistent respiratory symp-
toms develop. Grade: C; Quality: low; Benefit: intermediate;
Consensus: very good.
3) Females with TSC should undergo HRCT of the thorax in
the presence of otherwise unexplained respiratory symptoms.
Grade: B; Quality: low; Benefit: substantial; Consensus: very
good.
Should males with TSC be screened for LAM by HRCT?
LAM can occur in males with TSC but is very rare [5, 42, 44].
As males are less likely to be exposed to oestrogen containing
treatments early diagnosis of LAM is less likely to be of benefit
to patients.
Recommendations
1) Males with TSC and otherwise unexplained respiratory
symptoms should be investigated as dictated by their
symptoms; this may include HRCT scanning. Grade: C;
Quality: low; Benefit: intermediate; Consensus: very good.
2) Males without respiratory symptoms should not be screened
for LAM with HRCT. Grade: D; Quality: low; Benefit: negative;
Consensus: very good.
Is screening for LAM needed in females with sporadic
angiomyolipoma?
The prevalence of angiomyolipomas in sporadic LAM is 40–
50% and ,80% in TSC-LAM patients when screened by CT
[7, 45–47]. In TSC, angiomyolipomas are larger, much more
frequently bilateral and more prone to bleeding [48–52].
Recommendations
1) In patients with unilateral angiomyolipoma, no clinical
features of TSC and no pulmonary symptoms, screening for
LAM by HRCT may be performed.
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2) In patients with bilateral angiomyolipoma, screening for
TSC should be performed, with further LAM screening if TSC
is present. Grade: B; Quality: low; Benefit: substantial;
Consensus: very good.
PROGNOSIS
Estimation of prognosis
Predicting the prognosis of individual patients is difficult.
Histological extent of disease [20, 23] and some lung function
variables [20, 36, 53] have been found to be predictive, at
diagnosis, of either survival or more rapid deterioration of
lung function. LAM is less severe in TSC-LAM than sporadic-
LAM although this may reflect ascertainment bias [18, 54].
None of these predictors have been validated prospectively
and moreover, some of these variables may only reflect more
advanced disease at the time of diagnosis resulting in shorter
survival. TL,CO and FEV1 are likely to be the best current
indicators of disease progression and survival. Patients with
TSC-LAM may have a more indolent course than those with
sporadic LAM.
Recommendations
1) Lung biopsy does not provide prognostic information and
should not be performed for this purpose alone. Grade: D;
Quality: low; Benefit: negative; Consensus: very good.
2) Disease progression may be evaluated by repeating lung
function tests at 3–6 monthly intervals during the first year
following diagnosis then at 3–12 monthly intervals depending
on the severity and progression of the disease. Grade: C;
Quality: low; Benefit: intermediate; Consensus: very good.
Follow-up of patients with TSC-LAM with no pulmonary
symptoms
Sporadic LAM is generally a progressive disease characterised
by deteriorating lung function [4, 21]. In patients with TSC-
LAM and progressive disease regular follow-up and serial
lung function is recommended to detect and intervene early
where the clinical picture changes. In patients with TSC-LAM
and minimal symptoms the risk of severe LAM appears to be
lower than in those with sporadic LAM [18].
Recommendations
1) Regular follow-up by a respiratory specialist or serial lung
function studies may not be required for patients with TSC-
LAM with normal lung function after initial evaluation and
who have been stable after a period of observation of 1 yr.
Follow-up respiratory evaluation and lung function should be
performed if respiratory symptoms develop. Grade: expert
opinion/C; Quality: expert opinion; Benefit: small/weak;
Consensus: very good.
2) Other health professionals involved in the care of patients
with TSC and patients themselves should be informed that
patients experiencing respiratory symptoms should be seen by
a respiratory specialist. This may be in an information
document given to patients and general physicians. Grade:
expert opinion/C; Quality: expert opinion; Benefit: small/
weak; Consensus: very good.
MANAGEMENT
General advice and interventions
In common with other pulmonary diseases, patients with LAM
should be encouraged to maintain a normal weight and refrain
from smoking. The diagnosis of an orphan disease and its
consequences often leave patients with a feeling of isolation.
Patient groups can help with these issues and other practical
matters.
Advice for patients on pneumothorax
LAM is associated with an increased risk of pneumothorax
which occurs in ,40% of patients at presentation and 66% of
patients during the course of the disease [10, 55]. The estimated
rate of recurrence after the first episode in LAM is ,75% [29].
Recommendation
1) Patients with both sporadic and TSC-LAM including those
with no or minimal symptoms must be warned of the risk of
pneumothorax and told to seek urgent medical attention in the
event of symptoms of pneumothorax. Grade: A; Quality: fair;
Benefit: substantial; Consensus: very good.
Advice for patients and management of pregnancy
It is likely that pregnancy in LAM is associated with an
increased risk of pneumothorax and chylothorax [10, 56–60]. It
is suspected that pregnancy may accelerate the decline in lung
function [61]. It is likely that patients with poor baseline lung
function are less likely to tolerate a pneumothorax or chylous
effusion during pregnancy. There may be an increased risk of
bleeding from angiomyolipoma during pregnancy [62–65].
Recommendations
1) To become pregnant is the patients’ decision. However all
patients, including those with few or no symptoms, should be
informed that there is a greater risk of pneumothorax and
chylous effusion during pregnancy. Those with recurrent
pneumothorax or effusion outside pregnancy and those with
poor baseline lung function are at greater risk during
pregnancy. Grade: expert opinion/B; Quality: expert opinion;
Benefit: intermediate; Consensus: very good.
2) Females with LAM who are pregnant should receive
information, ideally pre-pregnancy or as soon after conception
as feasible to warn of the risk of pneumothorax, effusion and
bleeding from angiomyolipoma. Grade: expert opinion/B;
Quality: expert opinion; Benefit: intermediate; Consensus: very
good.
3) Patients with tuberous sclerosis should further receive
genetic counselling prior to conception. Grade: A; Quality:
good; Benefit: substantial; Consensus: very good.
4) Patients should be monitored during pregnancy by both a
pulmonary physician and an obstetrician informed about
LAM. Grade: expert opinion/B; Quality: expert opinion;
Benefit: intermediate; Consensus: very good.
5) It may be appropriate to discourage patients with severe
disease from becoming pregnant, this counsel being given on
an individual basis. Grade: expert opinion/B; Quality: expert
opinion; Benefit: intermediate; Consensus: very good.
S.R. JOHNSON ET AL. ERS TASK FORCE
c
EUROPEAN RESPIRATORY JOURNAL VOLUME 35 NUMBER 1 19
Avoidance of oestrogen including the contraceptive pill and
hormone replacement
Exogenous oestrogens may promote the progression of
pulmonary LAM in at least some cases [66–69].
Recommendation
1) Females with LAM should avoid oestrogen containing
treatments including the combined oral contraceptive pill and
hormone replacement therapy. Grade: C; Quality: low; Benefit:
intermediate; Consensus: very good.
Information for patients concerning air travel
Reports of pneumothorax occurring in flight have resulted in
females with LAM being advised not to travel by air [70].
Patients with sporadic and TSC-LAM with well preserved lung
function do not need to take specific precautions or avoid air
travel. Those with advanced disease should be evaluated for
the need for oxygen during flight to prevent hypoxaemia and
as they are less likely to tolerate pneumothorax.
Recommendations
1) Patients with sporadic or TSC-LAM and minimal symptoms
should not be discouraged from air travel. They should be
warned that they should not travel if new respiratory
symptoms have not been evaluated. Grade: C; Quality: low;
Benefit: intermediate; Consensus: very good.
2) Patients with advanced disease should be evaluated for the
need for oxygen during flight and should not travel if new
respiratory symptoms have not been evaluated. Those for
whom an untreated pneumothorax may have serious con-
sequences should consider alternatives to air travel. Grade: C;
Quality: low; Benefit: intermediate; Consensus: very good.
3) Patients with a known untreated pneumothorax, or a
pneumothorax treated within the previous month, should not
travel by air. Grade: B; Quality: low; Benefit: substantial;
Consensus: very good.
Pulmonary rehabilitation
Although there have been no specific studies examining the
impact of pulmonary rehabilitation in LAM, supporting
evidence of benefit may be extrapolated from other diseases
including chronic obstructive pulmonary disease (COPD) [71].
Recommendation
1) Pulmonary rehabilitation may be offered to patients with
LAM who are limited by dyspnoea. Grade: expert opinion/B;
Quality: expert opinion; Benefit: intermediate; Consensus: very
good.
Influenza and pneumococcal vaccination
Although the effect of prophylactic vaccination in patients with
LAM has not been tested, by analogy with COPD, it may be
proposed to patients with LAM and impaired lung function [72].
Recommendation
1) Influenza and pneumococcal vaccination should be offered
to patients with LAM. Grade: expert opinion/B; Quality:
expert opinion; Benefit: intermediate; Consensus: very good.
Assessment and management of osteoporosis
LAM is associated with reduced bone mineral density in a
significant proportion of patients [73]. In view of the rapid
deterioration in bone mineral density observed after lung
transplantation, early initiation of aggressive therapy in LAM
patients with severe lung disease and osteopenia at any bone
site is recommended. Weight-bearing exercise and strength
training should be encouraged.
Recommendations
1) Patients with LAM, especially those post-menopause,
should undergo periodic evaluation of bone mineral density.
Grade: B; Quality: low; Benefit: substantial; Consensus: very
good.
2) Those with osteoporosis should be treated the same as other
patients with osteoporosis. Grade: B; Quality: low; Benefit:
substantial; Consensus: very good.
3) In view of the rapid deterioration in bone mineral density
observed after lung transplantation, aggressive therapy for
osteoporosis should be initiated early in LAM patients with
severe lung disease and osteopenia at any bone site. In
addition to pharmacological therapy, weight-bearing exercise
and strength training should be encouraged because of the
growing evidence that exercise improves bone density. Grade:
B; Quality: low; Benefit: substantial; Consensus: very good.
Inhaled bronchodilators
One quarter of patients respond to inhaled bronchodilators
according to standard objective criteria and more may obtain
some clinical benefit [8, 36]. Patients who respond to
bronchodilators tend to have airflow obstruction and have a
greater rate of decline in FEV1. Although bronchiolar inflam-
mation is seen in some patients [36] the efficacy of inhaled
corticosteroids in LAM has not been assessed.
Recommendation
1) Inhaled bronchodilators should be trialled in patients with
airflow obstruction and continued if a response is observed.
Grade: B; Quality: low; Benefit: substantial; Consensus: very
good.
Hormone therapy: progesterone
There are no randomised placebo controlled trials of proges-
terone in LAM despite its widespread use [18]. Some case
series and reports suggested it to be effective in some patients.
However, drawing conclusions from case reports is prone to
bias as positive outcomes are more likely to be reported than
harmful or ineffective treatments. Similarly, more rapidly
declining patients are treated with progesterone. Such studies
have shown either no effect or worsening of lung function or
dyspnoea in the progesterone treated patients and in one case a
nonsustained reduction in rate of decline in TL,CO [4, 21].
Recommendations
1) Oral or intramuscular progesterone should not be used
routinely in patients with LAM. Grade: I; Quality: low: Benefit:
conflicting; Consensus: very good.
2) In patients with a rapid decline in lung function or
symptoms, intramuscular progesterone may be trialled.
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Grade: C; Quality: low; Benefit: small/weak; Consensus: very
good.
3) If used, progesterone may be given for 12 months with
clinical evaluation and lung function at 3 monthly intervals. If
lung function and symptoms continue to decline at the same
rate on progesterone treatment after one year, progesterone
should be withdrawn. Grade: expert opinion/C; Quality:
expert opinion; Benefit: small/weak; Consensus very good.
Hormone therapy: other anti-oestrogen interventions
Despite a number of case reports describing the use of
oophorectomy [74–78], tamoxifen [79–82] and GnRH agonists
[83–85] in LAM no confident data exist on the efficacy of any
anti-oestrogen strategy for LAM. One recent open label study
that examined 11 patients treated with the GnRH agonist
triptorelin found that no patients improved and the drug was
associated with a reduction in bone mineral density [86].
Recommendation
1) Hormone treatments other than progesterone should not be
used in patients with LAM. Grade: I; Quality: low; Benefit:
conflicting; Consensus: very good.
mTOR inhibitors
Inherited mutations of the TSC-1 or TSC-2 genes cause TSC
while acquired (somatic) mutations of either gene are
associated with sporadic LAM. The mTOR pathway is
constitutively activated in LAM [12, 13]. Two prospective
open-label clinical trials suggest that the mTOR inhibitor
sirolimus reduces angiomyolipoma volume [14, 15]. However,
the effect on bleeding from angiomyolipomas has not been
evaluated. Furthermore, the relative risk/benefit of treatment
has not been compared with that of other established
treatments of angiomyolipoma (i.e. catheter embolisation and
conservative surgery). The effect of mTOR inhibitors on
pulmonary function is unclear and their use can be associated
with adverse events. mTOR inhibitors may be a future
therapeutic option in patients with LAM and further studies
are required.
Recommendations
1) Sirolimus should not be prescribed routinely outside clinical
trials for pulmonary LAM. Patients with LAM should be
encouraged to participate in clinical trials whenever possible.
Grade: C; Quality: low; Benefit: small/weak; Consensus: very
good.
2) In renal angiomyolipoma mTOR inhibitors should not be
used as first-line therapy. Sirolimus may be considered on an
individual basis in patients with symptomatic angiomyoli-
poma or LAM-related masses not amenable to embolisation or
conservative surgery in experienced centres. Grade: C; Quality:
low; Benefit: small/weak; Consensus: very good.
3) In the current context of scientific uncertainty but possible
treatment benefit, sirolimus may be considered on an individual
basis in patients with rapid decline in lung function or
symptoms, after careful evaluation of risk/benefit ratio in an
experienced centre. When sirolimus is used, the effect of therapy
should be carefully monitored for tolerance and effect on lung
function at 3 monthly intervals. Sirolimus should be stopped
once patients are listed for active lung transplantation. Grade: C;
Quality: low; Benefit: small/weak; Consensus: very good.
COMPLICATIONS AND CO-MORBIDITIES
Management of pneumothorax
Pneumothorax occurs in the majority of patients, results in
significant hospital stays, and is frequently recurrent.
Conservative treatments are associated with higher rates of
recurrence than pleurodesis via chest tube or appropriate
surgical interventions [10, 55]. Lung transplantation in patients
with previous thoracic surgery or pleural procedures may be
associated with increased technical difficulty and an increased
risk or perioperative bleeding [38, 55, 87, 88].
Recommendations
1) Pneumothorax in LAM should ideally be managed jointly by
a chest physician and thoracic surgeon. Grade: C; Quality: low;
Benefit: intermediate; Consensus: very good.
2) Chemical pleurodesis may be performed at first pneu-
mothorax. Patients who do not respond to initial therapy
including pleurodesis, should undergo an appropriate surgical
procedure according to their clinical condition and local
expertise. Grade: C; Quality: low; Benefit: intermediate;
Consensus: very good.
3) Patients with second pneumothorax should have an
appropriate surgical procedure according to their clinical
condition and local expertise. Grade: C; Quality: low; Benefit:
intermediate; Consensus: very good.
4) When transplantation is considered, patients with a history
of pleurodesis or pleurectomy should be referred to trans-
plantation centres with experience of LAM to anticipate
possible pleural complications. Grade: C; Quality: low;
Benefit: intermediate; Consensus: very good.
5) A history of pleurodesis or pleurectomy should not be
considered a contraindication to lung transplantation in
patients with LAM. However, patients should be informed of
an increased risk of perioperative pleural bleeding. Grade: C;
Quality: low; Benefit: intermediate; Consensus: very good.
Management of chylothorax
Chylothorax in LAM may be almost asymptomatic or cause
marked dyspnoea. The interventions used [11, 37, 81, 89–94]
for the management of chylothorax in LAM should be
appropriate for the size and clinical impact of the effusion,
comorbid factors and local expertise [91]. A fat-free diet (with
or without oral supplementation of medium-sized triglycer-
ides) or fat-free total parenteral nutrition has been used
occasionally to minimise the volume of chyle formation [95].
For small effusions, observation or thoracocentesis may be
sufficient.
Recommendations
1) Patients with chylothorax may be placed on a fat-free diet,
with supplementation with mid-chain triglycerides. Grade:
expert opinion/C; Quality: expert opinion; Benefit: small/
weak; Consensus: very good.
2) For the treatment of symptomatic chylous pleural effusions,
the decision to intervene and technique used should be
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performed on an individual basis, based on clinical evaluation
including amount of chyle collected, recurrence of chylothorax,
respiratory condition of the patient and consideration of future
lung transplantation. Grade: expert opinion/B; Quality: expert
opinion; Benefit: intermediate; Consensus: very good.
Treatment and follow-up of angiomyolipoma
Although experience is based on data from case series, both
embolisation and nephron sparing surgery have been per-
formed safely without compromising renal function both in
elective cases [96, 97] and acute renal haemorrhage [98],
including during pregnancy [64]. Embolisation can be per-
formed for active bleeding, is less invasive and does not
require general anaesthesia but may need to be repeated.
Embolisation may be favoured over surgery in patients with
bleeding angiomyolipoma, although no trials have compared
the two strategies. The intervention used depends upon
technical factors associated with the tumour and local
expertise. When bleeding is not present, nephron sparing
surgery may be preferred when a malignant lesion is
suspected. Surgery with intra-operative frozen section biopsy
may be considered with the option to perform conservative or
radical surgery; the risk of a false diagnosis of carcinoma must
be borne in mind [99]. Decisions are best made electively after
screening for angiomyolipoma or in response to symptoms
rather than in the setting of an acute haemorrhage, early
detection of angiomyolipoma is therefore important.
Recommendations
1) Patients should be advised to seek urgent medical attention
in the presence of symptoms of bleeding angiomyolipoma.
Grade: B; Quality: low; Benefit: substantial; Consensus: very
good.
2) Embolisation should be the first-line treatment for bleeding
angiomyolipoma. Nephron sparing surgery is also acceptable
dependent upon local expertise. Grade: expert opinion/B;
Quality: expert opinion; Benefit: substantial; Consensus: very
good.
3) Embolisation should be performed as a first line therapy of
angiomyolipoma in elective cases, with nephron sparing
surgery indicated where a malignant lesion cannot be
excluded. Technical factors associated with the tumour blood
supply and local expertise should also be taken into account.
Grade: C; Quality: low; Benefit: intermediate; Consensus: very
good.
When is treatment of angiomyolipoma indicated in
asymptomatic patients?
The risk of bleeding is linked to angiomyolipoma size and is
clinically appreciable in tumours o4 cm in diameter and
where aneurysms are o5 mm [50, 100, 101].
Recommendations
1) Asymptomatic renal angiomyolipoma ,4 cm should not be
treated, but should be followed by yearly ultrasound unless
symptoms occur. Where ultrasound measurements are unreli-
able due to technical factors, CT or MRI should be performed.
Grade: B; Quality: low; Benefit: substantial; Consensus: very
good.
2) Renal angiomyolipomas .4 cm or with renal aneurysms
.5 mm in diameter are at an increased risk of bleeding, and
should be followed by ultrasound imaging twice yearly to
evaluate growth. Treatment by embolisation or nephron
sparing surgery should be considered. Grade: expert opi-
nion/A; Quality: expert opinion; Benefit: substantial;
Consensus: very good.
LUNG TRANSPLANTATION FOR LAM
LAM accounts for 1.1% of lung transplant recipients [102].
LAM compares favourably to patients transplanted for other
indications [38, 88, 103, 104]. In a recent survey the actuarial
survival of lung transplantation for LAM was 86% at 1 yr, 76%
at 3 yrs, and 65% at 5 yrs [104].
Referral criteria for lung transplantation
Due to the small number of patients treated and variable rates
of decrease in lung function, firm recommendations are
difficult to make. In a recent survey of patients undergoing
transplantation for LAM, most had severe airway obstruction
and were transplanted with a mean FEV1 of ,25% and DL,CO
of 27% predicted [104]. Patients should be considered for lung
transplantation when they reach New York Heart Association
(NYHA) functional class III or IV with severe impairment in
lung function and exercise capacity (V9O2,max ,50% pred,
hypoxaemia at rest). Transplantation in patients .65 yrs of age
may only be considered exceptionally.
Recommendation
1) Patients should be considered for lung transplantation when
they reach NYHA functional class III or IV with hypoxaemia at
rest, severe impairment in lung function and exercise capacity
(V9O2,max ,50% pred). Grade: A; Quality: fair; Benefit:
substantial; Consensus: very good.
Which type of transplantation is indicated in LAM?
Both single, and more commonly, bilateral lung transplantations
have been performed for LAM. Although a bilateral lung
transplant is associated with better post-transplant lung func-
tion and a reduction in LAM-related complications there is no
difference in survival between the two procedures [104, 105].
Recommendation
1) The choice of a single, or bilateral lung transplant in LAM
should be determined by surgical technical factors and organ
availability. Grade: B; Quality: fair; Benefit: intermediate;
Consensus: very good.
Special considerations related to lung transplantation for
patients with TSC
Patients with TSC have received successful lung transplanta-
tion for severe LAM [106, 107]. Although no TSC specific
problems have been identified, patients with TSC-LAM are
likely to have more comorbidities than those with sporadic
LAM. The impact of these processes and their treatment
require careful pre-transplant evaluation.
Recommendations
1) Patients with TSC in the context of LAM should not be
precluded from lung transplantation by TSC alone. Some
patients may have TSC related medical or cognitive problems
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which preclude transplantation. Grade: B; Quality: low;
Benefit: substantial; Consensus: very good.
2) TSC-LAM patients should have careful multi-disciplinary
assessment when being evaluated for lung transplantation.
Grade: B; Quality: low; Benefit: substantial; Consensus: very
good.
Does the presence of an angiomyolipoma affect lung
transplant suitability?
The detection of renal angiomyolipoma in LAM is important
preoperatively, as the risk of bleeding associated with a large
angiomyolipoma is well established. Renal angiomyolipomas
were detected in 35–38% of patients during pre-transplant
assessment [107, 108]. The presence of angiomyolipoma does
not increase the incidence of post-transplant renal insufficiency
[107, 108].
Recommendations
1) Angiomyolipoma may not be a contraindication to lung
transplantation but may affect transplant suitability, surgery
and postoperative follow-up. Grade: B; Quality: low; Benefit:
substantial; Consensus: very good.
2) The presence of renal angiomyolipoma should be sought in
the preoperative assessment, and those at risk of bleeding
should be treated prior to transplantation. Grade: B; Quality:
low; Benefit: substantial; Consensus: very good.
Should the possibility of recurrent LAM in the transplanted
lung be investigated post-transplantation?
LAM recurring in the transplanted lung of either single or
bilateral lung transplant is rare and generally asymptomatic.
Recurrent LAM has been identified at post mortem examination
or in biopsies performed for other purposes. Recurrent LAM
does not seem to affect survival post transplantation [38, 88,
104, 109–111].
Recommendation
1) Routine investigation for recurrent LAM post transplanta-
tion with biopsy should not be performed. Grade: D; Quality:
low; Benefit: negative; Consensus: very good.
Post-transplant immunosuppression regimen for LAM
The same immunosuppressive regimen is used as for other
indications [88, 103, 107, 112]. The morbidity resulting from
long-term immunosuppression is similar for LAM and non-
LAM recipients [88].
Recommendation
1) Post-transplant regimen for patients with LAM should be
the same as for other indications. Grade: C; Quality: low;
Benefit: intermediate; Consensus: very good.
CONCLUSION
We have generated the first international clinical guidelines for
LAM. As LAM is a multisystem rare disease, this required the
participation of a range of specialists from many countries,
particularly Europe and the USA. The absence of a strong
evidence base for this rare disease required the use of a
consensus technique to provide guidelines containing the best
synthesis of evidence and expert opinion. These guidelines
contain the first proposal of diagnostic criteria in LAM and
recommend investigations and work-up for patients, screening
of groups at risk for LAM, discussion of prognosis and
management. The overall aim of this document is to help
patients by achieving an earlier diagnosis and better care,
including in countries with differing levels of healthcare
resources. The guidelines will be reviewed regularly or in real
time should a major advance occur.
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